Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.
Lipocine Inc. (NASDAQ: LPCN) is a biopharmaceutical company that publicly describes itself as leveraging a proprietary technology platform to develop therapeutics with effective oral delivery. News about Lipocine often centers on clinical trial milestones, regulatory interactions, and partnering activity related to its oral drug candidates.
A key focus of recent news is LPCN 1154, an oral formulation of brexanolone in development for the potential treatment of postpartum depression (PPD). Company press releases highlight the initiation of a pivotal Phase 3 trial, first patient dosing, enrollment progress, interim safety reviews by an independent Data Safety Monitoring Board, and plans to use Phase 3 data to support a 505(b)(2) NDA submission. Updates also describe the outpatient design of the trial and its target population of women with severe PPD.
News flow also covers LPCN 2401, an oral proprietary anabolic androgen receptor agonist being evaluated in obesity‑related settings. Lipocine has reported Phase 2 clinical data showing changes in body composition and liver‑related measures in men with obesity and metabolic dysfunction associated steatohepatitis, and has presented these data at the ObesityWeek meeting. Additional releases discuss regulatory status and development plans for proof‑of‑concept studies.
Other recurring topics include LPCN 2101 for the potential treatment of epilepsy, with announcements about abstract acceptances and poster presentations at the American Epilepsy Society annual meeting, as well as corporate updates on financial results, TLANDO licensing and royalty revenue, and participation in investor conferences. Investors and observers can use the LPCN news stream to follow clinical progress, safety updates, licensing developments, and strategic communications that the company files or references in its SEC reports.
Lipocine (NASDAQ: LPCN) has initiated a Phase 3 trial for LPCN 1154 (oral brexanolone) for treating postpartum depression (PPD). The registration-enabling trial follows successful pharmacokinetic bridge study results showing comparable exposure between LPCN 1154 and the reference drug.
The trial design features a two-arm, randomized, blinded study comparing LPCN 1154 to placebo in women aged 15 and older with severe PPD. Key aspects include:
- 48-hour at-home self-administration dosing period
- First patient dosing expected in Q2/2025
- Primary endpoint: Change from baseline in Hamilton Depression Rating Scale (HAM-D)
- Secondary endpoints: Changes in Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A)
The trial aims to support a global registration package for LPCN 1154, potentially positioning it as a first-line option for rapid PPD symptom relief.
Lipocine (NASDAQ: LPCN) reported financial results for 2024, showing a net income of $8,400 compared to a $16.4M loss in 2023. Revenue reached $11.2M, primarily from license agreements with Verity Pharma, SPC Korea, and Pharmalink for TLANDO commercialization.
Key developments include: FDA requiring additional safety and efficacy study for LPCN 1154 (oral brexanolone) for postpartum depression treatment, with Phase 3 study initiation expected in Q2 2025; positive qEEG study data for oral brexanolone; and Fast Track designation for LPCN 1148 for sarcopenia in decompensated cirrhosis patients.
The company maintained strong liquidity with $21.6M in cash and equivalents as of December 31, 2024. R&D expenses decreased to $7.4M from $10.2M in 2023, while G&A expenses remained stable at $5.0M.
Lipocine Inc (NASDAQ: LPCN) announced significant FDA labeling changes for testosterone products following the TRAVERSE clinical trial and post-market blood pressure studies. The FDA has removed the Boxed Warning related to cardiovascular risks from testosterone product labels, while maintaining 'Limitation of Use' language for age-related hypogonadism.
The updated labels will include TRAVERSE trial results and product-specific information on blood pressure effects. These changes are expected to benefit Lipocine's approved testosterone replacement therapy and its development pipeline, which includes candidates for obesity management (LPCN 2401), liver cirrhosis (LPCN 1148), and metabolic dysfunction-associated steatohepatitis (LPCN 1144).
The company has an exclusive license agreement with Verity Pharma since 2024 for marketing rights in the United States and Canada, pending approval.
Lipocine (NASDAQ: LPCN) has received updated FDA guidance for LPCN 1154, its postpartum depression (PPD) treatment candidate. The FDA has indicated that beyond the previously completed PK bridge data, an additional efficacy and safety study in the target population will be required for 505(b)(2) NDA submission.
Following comparable exposure results between LPCN 1154 and the reference drug in the completed PK bridge study, Lipocine is planning to proceed with a phase 3 safety and efficacy study. The company views this requirement as an opportunity to generate valuable safety and depression symptom relief data for product labeling and potential clinical investigation exclusivity for a 48-hour, oral treatment option. Additionally, the planned study will explore oral brexanolone's potential in treating anxiety disorders.
Lipocine (NASDAQ: LPCN) has received Fast Track Designation from the FDA for LPCN 1148, targeting sarcopenia treatment in patients with decompensated cirrhosis. The designation follows positive results from a Phase 2 proof-of-concept study where LPCN 1148, an oral prodrug of bioidentical testosterone, demonstrated improvements in sarcopenia and associated clinical outcomes.
LPCN 1148 aims to be a 'First in Class' treatment where no current therapy exists. The Fast Track status enables benefits including more frequent FDA meetings, enhanced communication about clinical trial design, eligibility for Accelerated Approval and Priority Review, and Rolling Review submission options for the New Drug Application (NDA).
Lipocine announced the publication of LPCN 1148's Phase 2 clinical trial results in Hepatology journal and its discussion at The Liver Meeting 2024. The study evaluated LPCN 1148 in men with cirrhosis and sarcopenia awaiting liver transplantation. At 24 weeks, LPCN 1148 showed significant improvement in sarcopenia compared to placebo and resulted in fewer episodes of overt hepatic encephalopathy (OHE), despite patients being on background therapies. The treatment also demonstrated beneficial effects on muscle quality, hemoglobin, and patient-reported symptoms. LPCN 1148 is positioned as a potential 'First in Class' product for OHE and sarcopenia indications.
Lipocine Inc (NASDAQ: LPCN) reported Q3 2024 financial results with a net loss of $2.2 million ($0.44 per share), compared to a $6.7 million loss in Q3 2023. The company had $19.8 million in cash and equivalents as of September 30, 2024. Key developments include positive results from LPCN 1154's qEEG study for postpartum depression treatment, with NDA submission targeted for end of 2024. Lipocine signed exclusive distribution agreements for TLANDO in GCC countries and South Korea. For the nine months ended September 30, 2024, revenue was $7.7 million, primarily from licensing, with a net loss of $1.8 million.
Lipocine Inc. (NASDAQ: LPCN) has entered into a license, development and supply agreement with SPC Korea for exclusive marketing rights of TLANDO® in South Korea. The agreement includes an upfront payment, potential regulatory and sales milestone payments, royalties on net commercial sales, and a supply price arrangement. SPC Korea will be responsible for obtaining regulatory approval in South Korea. This partnership aims to expand TLANDO's global reach and address unmet medical needs in the South Korean market.
Lipocine Inc. (NASDAQ: LPCN) announced positive data from its quantitative Electroencephalogram (qEEG) study of oral brexanolone, a neuroactive steroid being developed for post-partum depression (PPD). The study, conducted on 12 healthy postmenopausal females, showed robust central nervous system (CNS) activity with concentration- and time-dependent post-dose changes in qEEG.
Key findings include:
- Significant increases in theta and alpha1 band power in posterior cortical regions
- Decrease in alpha2 band power
- Considerable beta band amplitude increase across all cortical brain areas
- Rapid onset of effects (as early as 2 hours) with maximum impact at 4 hours post-dose
- Effects lasting up to 12 hours post-dose
These results confirm GABAA positive allosteric modulation and support the potential utility of oral brexanolone in treating various neuropsychiatric indications, including depression, anxiety, essential tremor, and epilepsy. The safety profile was consistent with previous clinical studies, showing minimal CNS depressant effects.
Lipocine Inc. (NASDAQ: LPCN) has announced an exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO®, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries. The agreement covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Under the terms of the agreement, Lipocine received an upfront payment from Pharmalink. Upon obtaining Marketing Authorizations in individual GCC countries, Lipocine will provide TLANDO drug product to Pharmalink at an agreed transfer price. Pharmalink will have exclusive rights to TLANDO in the GCC region and will be responsible for promotion, distribution, and sale of the product in the territory.
This partnership aligns with Lipocine's global strategy to expand the availability of TLANDO and make it broadly accessible. Pharmalink's expertise and established network in the GCC region make them an ideal partner to support the adoption and growth of TLANDO in these markets.